לנוחיות השימוש, המידע ערוך בשתי טבלאות.
אחת לפי שמות התרופות והשניה לפי שמות הצמחים, בסדר אלפאביתי.
רשימת התרופות מסודרת לפי השם הגנרי של התרופה.
אם אתם לא בטוחים בשם, ניתן לחפש ישירות בעזרת פונקציית החיפוש (CTRL+F).
המקורות למידע מפורטים בטבלה המסודרת על פי הצמחים.
מסיבות טכניות, העמוד עדיין אינו ניתן לצפיה בסלולר.
הטבלה המלאה זמינה למנויי האתר בלבד. לרכישת מנוי >>
הטבלה המלאה זמינה למנויי האתר בלבד. לרכישת מנוי >>
1. Kojima R, Toyama Y, Ohnishi ST. Protective effects of an aged garlic extract on doxorubicin-induced cardiotoxicity in the mouse. Nutr Cancer. 22:163-173. 1994.
2. Dwivedi C et al. Effects of oil-soluble organosulfur compounds from garlic on doxorubicin-induced lipid peroxidation. Anticancer Drugs .9:291-294 1998.
3. Thabrew MI et al. Protection by garlic against Adriamycin-induced alterations in the oxido-reductive status of mouse red blood cells. Phytother Res . 14:215-217 2000.
4. Mukherjee S et al. Protection against acute Adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-α expression. BMC Pharmacol . 3:16. 2003.
5. Lang A et al. Allicin inhibits spontaneous and TNF-α induced secretion of proinflammatory cytokines and chemokines from intestinal epithelial cells . Clin Nutr . 23:1199-1208 2004.
6. Horie T et al. . Protective effect of aged garlic extract on the small intestinal damage of rats induced by methotrexate administration. Planta Med . 65:545-548 1999.
7. Horie T et al. Alleviation by garlic of antitumor drug-induced damage to the intestine. J Nutr . 131:1071S-1074S 2001.
8. Khosla P, Karan RS, Bhargava VK. Effect of garlic oil on ethanol induced gastric ulcers in rats. Phytother Res. 18:87-91 2004.
9. Meijerman I, Beijnen JH, Schellens JHM. Herb-drug interactions in oncology: Focus on mechanisms of induction. Oncologist. 11(7): 742-752 2006.
10. Piscitelli SC et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis . 34(2): 234-238 2002.
11. Foster BC et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci .4(2): 176-184. 2001.
12. Kuang YH et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol . 79(2): 154-161. 2010.
13. Azzariti A et al. Tyrosine kinase inhibitors and multidrug resistance proteins: Interactions and biological consequences. Cancer Chemother Pharmacol. Jun 4, 2009.
14. Colabufo NA et al. Bicalutamide failure in prostate cancer treatment: Involvement of Multi Drug Resistance proteins. Eur J Pharmacol . 601(1-3): 38-42 2008.
15. AstraZeneca Pharmaceuticals LP. . Casodex® (bicalutamide) oral tablets [package insert]. Wilmington, DE. 2003.
16. Cox MC et al. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res. Aug 1;12(15):4636-40. 2006 .
17. Wyeth Pharmaceuticals Inc. . Torisel® kit (temsirolimus) injection [package insert]. Philadelphia, PA. 2008.
18. Tang JC et al. Effect of the water extract and ethanol extract from traditional Chinese medicines Angelica sinensis (Oliv.) Diels, Ligusticum chuanxiong Hort. and Rheum palmatum L. on rat liver cytochrome P450 activity. Phytother Res .20(12): 1046-1051. 2006.
19. Lau CB et al. Use of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: Is it appropriate? Menopause. 12(6): 734-740 2005.
20. Stargrove MB, Treasure J, McKee DL. Herb, Nutrient, and Drug Interactions. Elsevier. 2008.
21. Duan P, Wang Z . Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor. Zhongguo Zhong Xi Yi Jie He Za Zhi . 22:515-517. 2002.
22. Wei X, Zhang J, Li J, Chen S. Astragalus mongholicus and Polygonum multiflorum’s protective function against cyclophosphamide inhibitory effect on thymus. Am J Chin Med . 32:669-680. 2004.
23. Zou Y-h, Liu X-m. Effect of astragalus injection combined with chemotherapy on quality of life in patients with advanced non–small cell lung cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi . 23:733-735 2003.
24. Lee KY, Jeon YJ. Macrophage activation by polysaccharide isolated from Astragalus membranaceus. Int Immunopharmacol. 2005;5:1225-1233.
25. McCulloch M et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006.
26. Zhao KS, Mancini C, Doria G. Enhancement of the immune response in mice by Astragalus membranaceus extracts. Immunopharm. 20:225-234 1990.
27. Chu DT, Wong WL, Mavligit GM. Immunotherapy with Chinese medicinal herbs. II. Reversal of cyclophosphamide-induced immune suppression by administration of fractionated Astragalus membranaceus in vivo. J. Clin. Lab. Immunol. 25(3):125-129 1988.
28. Yoshida Y et al. Immunomodulating activity of Chinese medicinal herbs and Oldenlandia diffusa in particular. Int. J. Immunopharm. 19(7):359-370 1997.
29. Zhu X-L, Zhu B-D. Mechanisms by which Astragalus membranaceus injection regulates hematopoiesis in myelosuppressed mice. Phytother. Res. 21(7):663-667 2007.
30. Qi F et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends. Feb; 9(1):16-34. 2015 .
31. Auyeung KK, Law PC, Ko JK. Combined therapeutic effects of vinblastine and Astragalus saponins in human colon cancer cells and tumor xenograft via inhibition of tumor growth and proangiogenic factors. Nutr Cancer. 66(4):662-74 2014.
32. Chu DT et al. Fractionated extract of Astragalus membranaceus, a Chinese medicinal herb, potentiates LAK cell cytotoxicity generated by a low dose of recombinant interleukin-2. . J Clin Lab Immunol. 26:183-187 1988.
33. Sun Y et al. Immune restoration and/or augmentation of local graft versus host reaction by traditional Chinese medicinal herbs. Cancer . 52:70-3 1983.
34. Wang DC. Influence of Astragalus membranaceus (AM) polysaccharide FB on immunologic function of human periphery blood lymphocyte. . Zhonghua Zhong Liu Za Zhi . 11:180-183 1989.
35. Chen Q, Qin R, Fang Y, Li H. Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway. Cell Physiol Biochem. 36(3):956-65 2015.
36. Guo JJ et al. Comparison of potentially hepatotoxic drugs among major US drug compendia. Res Social Adm Pharm. 1(3): 460-479 2005.
37. Donald S et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. Cancer Res . 63(18): 5902-5908 2003.
38. Pharma Mar S.A. Yondelis® (trabectedin) 0.25mg and 1mg powder for concentrate for solution for infusion [package insert]. Madrid, Spain. 2009.
39. Mazzanti G et al. Hepatotoxicity from green tea: A review of the literature and two unpublished cases. Eur J Clin Pharmacol . 65(4): 331-341 2009.
40. American Society of Health-System Pharmacists. AHFS Drug Information. 2007 ed. Bethesda, MD. American Society of Health System Pharmacists Inc. . [Online] 2007.
41. Netsch MI et al. Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med. 72(6): 514-520. 2006.
42. Yang SP, Raner GM. Cytochrome P450 expression and activities in human tongue cells and their modulation by green tea extract. Toxicol Appl Pharmacol . 202(2): 140-150. 2005.
43. Chen L et al. Caffeine induces cytochrome P4501A2: Induction of CYP1A2 by tea in rats. . Drug Metab Dispos . 24(5): 529-533 1996.
44. Muto S et al. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. . Mutat Res . 479(1-2): 197-206. 2001; .
45. Chow HH et al. Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev . 15(12): 2473-2476. 2006.
46. Donovan JL et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos . 32(9): 906-908 2004; .
47. Jorge OA, Jorge AD. Hepatotoxicity associated with the ingestion of Centella asiatica. Rev Esp Enferm Dig . 97(2): 115-124 2005.
48. Brinkhaus B et al. Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica. Phytomedicine . 7(5): 427-448 2000.
49. Sakina MR, Dandiya PC. A psycho-neuropharmacological profile of Centella asiatica extract. Fitoterapia . 61(4): 291-296 1990.
50. Cauffield JS, Forbes HJ. Dietary supplements used in the treatment of depression, anxiety, and sleep disorders. Lippincotts Prim Care Pract . 3(3): 290-304 1999.
51. Wijeweera P et al. Evaluation of anxiolytic properties of Gotukola - (Centella asiatica) extracts and asiaticoside in rat behavioral models. Phytomedicine . 13(9-10): 668-676. 2006; .
52. Solimando DAJ. Drug Information Handbook for Oncology. 6th ed. Hudson, Ohio: Lexi-comp . 2007.
53. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat . 90(3):233-9 2005.
54. Einbond LS et al. Actein and a fraction of black cohosh potentiate antiproliferative effects of chemotherapy agents on human breast cancer cells. Planta Med. Oct;72(13):1200-6. 2006 .
55. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat . 90(3): 233-239 2005.
56. Gurley BJ et al. In vivo Effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther . 77(5): 415-426 2005.
57. Hernandez Munoz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas, 44(Suppl. 1):A59-A65. 2003.
58. Rostock M et al. Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints - a prospective observational study. Gynecol Endocrinol. Oct;27(10):844-8. 2011 .
59. Jacobson JS et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol. May 15;19(10):2739-45, 2001 .
60. Maeng HJ et al. P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci . 91:2614–2621 2002.
61. Chen Q, Qin R, Fang Y, Li H. Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway. Cell Physiol Biochem ;36(3):956-65 2015.
62. Chen GZ et al. Effects of Cordyceps sinensis on murine T lymphocyte subsets. Chin Med J (Engl) . 104(1): 4-8. 1991.
63. Chen YJ et al. Effect of Cordyceps sinensis on the proliferation and differentiation of human leukemic U937 cells. Life Sci . 60(25): 2349-2359. 1997.
64. Qian ZM, Xu MF, Tang PL. Polysaccharide peptide (PSP) restores immunosuppression induced by cyclophosphamide in rats. Am. J. Chin. Med. 25(1):27-35 1997.
65. Shiu WCT, Leung TWT, Tao M. A clinical study of PSP on peripheral blood counts during chemotherapy. Phytother. Res. 6:217-218 1992.
66. Stargrove MB, Treasure J, McKee DL. Herb, Nutrient, and Drug Interactions. Elsevier. 2008.
67. Morsy MA et al. Curcumin ameliorates methotrexate-induced nephrotoxicity in rats. Adv Pharmacol Sci. 2013:387071 2013.
68. Hemeida RA, Mohafez OM. Curcumin attenuates methotraxate-induced hepatic oxidative damage in rats. J Egypt Natl Canc Inst. Jun;20(2):141-8. 2008 .
69. van't Land B et al. Role of curcumin and the inhibition of NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury. Leukemia. Feb;18(2):276-84. 2004 .
70. Si M et al. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein. Chin Med J (Engl). Nov;126(21):4116-23 2013 .
71. Dhanasekaran S et al. Augmented sensitivity to methotrexate by curcumin induced overexpression of folate receptor in KG-1 cells. Biochimie. Aug;95(8):1567-73. 2013 .
72. Chen WC et al. Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. J Agric Food Chem. Dec 4;61(48):11817-24. 2013 .
73. Guo O et al. Enhanced 4T1 breast carcinoma anticancer activity by co-delivery of doxorubicin and curcumin with core-shell drug-carrier based on heparin modified poly(L-lactide) grafted polyethylenimine cationic nanoparticles. J Biomed Nanotechnol. 2014 Feb;10(2):227-3.
74. Qian H, Yang Y, Wang X. Curcumin enhanced adriamycin-induced human liver-derived Hepatoma G2 cell death through activation of mitochondria-mediated apoptosis and autophagy. Eur J Pharm Sci. 2011 Jun 14;43(3):125-31.
75. Lü YH et al. In vitro pharmacodynamic interactions of antitumor effect of the combination of adriamycin and curcumin evaluated by the parameter method and the response surface. Yao Xue Xue Bao. 2010 Aug;45(8):1039-42.
76. Hosseinzadeh L et al. Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem Toxicol. 2011 May;49(5):1102-9.
77. Meiyanto E et al. Curcumin and its analogues (PGV-0 and PGV-1) enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF-kB activation. Asian Pac J Cancer Prev. 2014;15(1):179-84.
78. Pramanik D et al. A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicin-associated cardiomyopathy. Oncotarget. 2012 Jun;3(6):640-50.
79. Duan J et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. Int J Pharm. 2012 Apr 15;426(1-2):193-201.
80. Misra R, Sahoo SK. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm. 2011 Jun 6;8(3):852-66.
81. Sen GS et al. Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer. J Biol Chem. 2011 Dec 9;286(49):42232-47.
82. Yu LL et al. Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-κB transcription factor. Oncol Rep. 2011 Nov;26(5):1197-203.
83. Goel A, Aggarwal BB. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Nutr Cancer. 2010;62(7):919-30.
84. Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem. 2007 Jul;102(2):522-38.
85. Carlson LJ et al. Polymeric Micellar Co-delivery of Resveratrol and Curcumin to Mitigate In Vitro Doxorubicin-Induced Cardiotoxicity. J Pharm Sci. 2014 Aug;103(8):2315-22.
86. Choi BH et al. Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett. 2008 Jan 18;259(1):111-8.
87. Sadzuka Y et al. Beneficial effects of curcumin on antitumor activity and adverse reactions of doxorubicin. Int J Pharm. 2012 Aug 1;432(1-2):42-9.
88. Wang H et al. Increase of therapeutic activity of doxorubicin by long circulating liposomes in combination with curcumin. Pharmazie. 2011 Nov;66(11):871-4.
89. Su CC et al. Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. Phytother Res. 2010 Feb;24(2):189-92.
90. Mohamad RH et al. The role of Curcuma longa against doxorubicin (adriamycin)-induced toxicity in rats. J Med Food. 2009 Apr;12(2):394-402.
91. Imbaby S et al. Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats. Hum Exp Toxicol. 2014 Mar 19;33(8):800-813.
92. Swamy AV et al. Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol. 2012 Jan;44(1):73-7.
93. Bayet-Robert M et al. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol. Ther. 9(1):8-14 2010.
94. Epelbaum R et al. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer. 62(8):1137-1141 2010.
95. Kanai M et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol. Jun 71(6):1521-30., 2013 .
96. Somasundaram S et al. Dietary cucumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 62:3868-3875 2002.
97. Dhandapani KM, Mahesh VB, Brann DW. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors. J Neurochem.Jul; 102(2):522-38. 2007 .
98. Saleh EM et al. Antagonism between curcumin and the topoisomerase II inhibitor etoposide: a study of DNA damage, cell cycle regulation and death pathways. Cancer Biol Ther. Sep; 13(11):1058-71. 2012 .
99. Venkatesan N, Chandrakasan G. Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant. Mol Cell Biochem . 142:79-87. 1995.
100. Arafa HM. Uroprotective effects of curcumin in cyclophosphamide-induced haemorrhagic cystitis paradigm. Basic Clin Pharmacol Toxicol. May; 104(5):393-9. 2009.
101. Xiao H, Zhang KJ. Antiproliferative effect of curcumin combined with cyclophosmide on the growth of human lymphoma cell line HT/CTX with drug resistance and its relation with FA/BRCA pathway. Zhongguo Shi Yan Xue Ye Xue Za Zhi. Aug; 16(4):804-8. 2008.
102. Ibrahim MA et al. Protective effect of curcumin and chlorophyllin against DNA mutation induced by cyclophosphamide or benzo[a]pyrene. Z Naturforsch C. Mar-Apr; 62(3-4):215-22. 2007.
103. Somasundaram et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 62:3868-3875 Cancer Res . 63:5165-5166; author reply 5166-5167. 2003.
104. Shishodia S, Aggarwal BB. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, I B kinase activation and NF- B-regulated gene expression. Oncogene. 25:1463- 1473 2006.
105. Lersch C et al. Nonspecific immunostimulation with low doses of cyclophosphamide (LDCY), thymostimulin, and Echinacea purpurea extracts (Echinacin) in patients with far advanced colorectal cancers: preliminary results. Cancer Invest . 1992;10:343-348.
106. Lersch C et al. Stimulation of the immune response in outpatients with hepatocellular carcinomas by low doses of cyclophosphamide (LDCY), Echinacea purpurea extracts (Echinacin) and thymostimulin. Arch Geschwulstforsch . 1990;60:379-383.
107. Melchart D et al. Polysaccharides isolated from Echinacea purpureaherba cell cultures to counteract undesired effects of chemotherapy: a pilot study. Phytother Res. 2002;16:138-142.
108. Currier NL, Miller SC. Natural killer cells from aging mice treated with extracts fromEchinacea purpurea are quantitatively and functionally rejuvenated. Exp Gerontol . 2000;35:627-639.
109. Goey AK et al. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel. Br J Clin Pharmacol. Sep;76(3):467-74. 2013.
110. Bossaer JB, Odle BL. Probable etoposide interaction with Echinacea. J Diet Suppl. Jun;9(2):90-5. 2012 .
111. Stargrove MB, Treasure J, McKee DL. Herb, Nutrient, and Drug Interactions. Elsevier. 2008.
112. Brekhman II. Report on the use of Eleutherococcus with breast cancer patients. Eleutherococcus: Clinical Data. Institute of Oncology, Georgia: USSR Foreign Trade Publication, Medexport, USSR; 1970.
113. Hacker B, Medon PJ. Cytotoxic effects of Eleutherococcus senticosus aqueous extracts in combination with N6-(δ-2-isopentenyl)-adenosine and 1-β-D-arabinofuranosylcytosine against L1210 leukemia cells. J Pharm Sci . 1984;73:270-272.
114. Monakhov BV. Reduction of toxicity of some antiblastoma drugs by Eleutherococcus extract. Vopr Onkol (Russian). 1967;13:71-76.
115. Yonezawa M, Katoh N, Takeda A. Radiation protection by Shigoka extract on split-dose irradiation in mice. J Radiat Res (Tokyo) . 1989;30:247-254.
116. Miyanomae T, Frindel E. Radioprotection of hemopoiesis conferred by Acanthopanax senticosus Harms (Shigoka) administered before or after irradiation. Exp Hematol . 1988;16:801-806.
117. Minkova M, Pantev T. Effect of Eleutherococcus extract on the radioprotective action of adeturone. Acta Physiol Pharmacol Bulg . 1987;13:66-70.
118. Bespalov VG et al. Comparative effects of difluoromethylornithine and tincture of Siberian ginseng root on radiation carcinogenesis and life span in rats. Adv Gerontol. .2012;25(2):293-300.
119. Yarbro CH et al. Eds. Cancer Nursing: Principles and Practice. 6th ed. Portland, OR: Jones & Bartlett Publishers, Inc. 2005.
120. Henderson GL et al. Effects of ginseng components on c-DNA expressed cytochrome P450 enzyme catalytic activity. Life Sci . 65(15): PL209-214. 1999.
121. Takara K et al. Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells. Biol Pharm Bull . 2005;28:138–14.
122. Yang L et al. Icariin from Epimedium brevicornum Maxim promotes the biosynthesis of estrogen by aromatase (CYP19). J Ethnopharmacol. Feb ;145(3):715-721, 2013.
123. McKenna D, Jones K, Hughes K, Humphrey S. Botanical Medicines (Reishi) . 2nd ed. Binghamton, NY: Haworth Press; 2002:825-85.
124. Kupin V. A new biological response modifier—Ganoderma lucidum—and its application in oncology. The 4th International Symposium on Ganoderma lucidum. Seoul National University. 1992:36-39.
125. Wong KL et al. Antioxidant activity of Ganoderma lucidum in acute ethanol-induced heart toxicity. Phytother Res . 2004;18:1024-1026.
126. Cao QZ, Lin ZB. Ganoderma lucidum polysaccharides peptide inhibits the growth of vascular endothelial cell and the induction of VEGF in human lung cancer cell. Life Sci . 2006;78:1457-1463.
127. Zhou H et al. Effect of recombinant Ganoderma lucidum immunoregulatory protein on cyclophosphamide-induced leukopenia in mice. Immunopharmacol Immunotoxicol. Jun;35(3):426-33.
128. Lu Z, Lin Z. Antagonistic effect of Ganoderma polysaccharides peptide against immunosuppression caused by repetitive in vivo treatments of morphine. International Symposium on Ganoderma Research. Program and Abstracts vol. Beijing: Beijing Medical Univers. 1994:82.
129. Chen WC, Hau DM, Lee SS. Effects of Ganoderma lucidum and krestin on cellular immunocompetence in gamma-ray-irradiated mice. Am J Chin Med . 1995;23:71-80.
130. Kubo N et al. Protective effects of a water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia and Agaricus blazei murill against X-irradiation in B6C3F1 mice: increased small intestinal crypt survival and prolongation of average time to animal. Int J Mol Med . 2005;15:401-406.
131. Yue QX et al. Interaction of Ganoderma triterpenes with doxorubicin and proteomic characterization of the possible molecular targets of Ganoderma triterpenes. Cancer Sci. .2008;99: 1461-1470.
132. Jin X, Ruiz Beguerie J, Sze DM, Chan GC. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev. Apr 5;4:CD007731 2016 .
133. Suárez-Arroyo IJ et al. Ganoderma lucidum combined with the EGFR tyrosine kinase inhibitor, erlotinib synergize to reduce inflammatory breast cancer progression. J. Cancer . 2016, 7, 500–511.
134. Suárez-Arroyo IJ et al. Ganoderma spp.: A Promising Adjuvant Treatment for Breast Cancer. Medicines . 2017, 4(1), 15.
135. Brouwer CA et al. Long-term cardiac follow-up in survivors of a malignant bone tumour. . Ann Oncol . 2006.
136. Yi SY, Nan KJ, Chen SJ. Effect of extract of Ginkgo biloba on doxorubicin-associated cardiotoxicity in patients with breast cancer. Zhongguo Zhong Xi Yi Jie He Za Zhi. Jan;28(1):68-70. 2008.
137. Fukaya H, Kanno H. Experimental studies of the protective effect of Ginkgo biloba extract (GBE) on cisplatin-induced toxicity in rats. Nippon Jibiinkoka Gakkai Kaiho . 1999.
138. Ozturk G et al. The effect of Ginkgo extract EGB761 in cisplatin-induced peripheral neuropathy in mice. Toxicol Appl Pharmacol . 2004.
139. Liu SQ et al. Ginkgo biloba extract enhances chemotherapy sensitivity and reverses chemoresistance through suppression of the KSR1-mediated ERK1/2 pathway in gastric cancer cells. Oncol Rep. Jun;33 2015 .
140. Yin OQ et al. Pharmacogenetics and herb-drug interactions: Experience with Ginkgo biloba and omeprazole. Pharmacogenetics . 14(12): 841-850 2004.
141. Taki Y et al. Time dependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in rats. J Pharmacol Sci . 109(3): 459-462 2009.
142. Yale SH, Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med . 11(3): 433-439 2005.
143. Li L et al. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res . 26(4): 872-882 2009.
144. Fehske CJ, Leuner K, Müller WE. Ginkgo biloba extract (EGB761) influences monoaminergic neurotransmission via inhibition of NE uptake, but not MAO activity after chronic treatment. Pharmacol Res . 60(1): 68-73 2009.
145. Sigma-Tau Pharmaceuticals Inc. Matulane®(procarbazine hydrochloride) capsules [package insert]. Gaithersburg, MD . 2004.
146. Lee CK et al. Effects of the licorice extract against tumor growth and cisplatin-induced toxicity in a mouse xenograft model of colon cancer. Biol Pharm Bull . 30(11): 2191-2195. 2007.
147. Kent UM et al. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos .30(6): 709-715. 2002.
148. Mu Y et al. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther . 316(3): 1369-1377 2006.
149. Paolini M et al. Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes. Cancer Lett . 145(1-2): 35-42. 1999.
150. —. Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases. Life Sci . 62(6): 571-582. 1998.
151. Shon JH et al. Effect of licorice (radix glycyrrhizae) on the pharmacokinetics (PK) and pharmacodynamics (PD) of midazolam in healthy subjects. Clin Pharmacol Ther . 69(2): P78. 2001.
152. Tamir S et al. Estrogenic and antiproliferative properties of glabridin from licorice in human breast cancer cells. Cancer Res . 60(20): 5704-5709. 2000; .
153. Walker BR, Edwards CR. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am . 23(2): 359-377. 1994.
154. Sundaram MB, Swaminathan R. Total body potassium depletion and severe myopathy due to chronic liquorice ingestion. Postgrad Med J . 57(663): 48-49. 1981.
155. Nanba H, Kubo K. Effect of Maitake D-fraction on cancer prevention. Ann. N.Y. Acad. Sci. 833:204-207, 1997.
156. Finkelstein MP et al. Chemosensitization of carmustine with Maitake beta-glucan on androgen-independent prostatic cancer cells: involvement of glyoxalase I. J. Altern. Compl. Med. 8(5):573-580, 2002.
157. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom . 18(19): 2273-2281. 2004.
158. Fiebich BL et al. Inhibition of TNF-alpha synthesis in LPS-stimulated primary human monocytes by Harpagophytum extract SteiHap 69. Phytomedicine . 8(1): 28-30 2001.
159. Chen Q, Qin R, Fang Y, Li H. Berberine Sensitizes Human Ovarian Cancer Cells to Cisplatin Through miR-93/PTEN/Akt Signaling Pathway. Cell Physiol Biochem. 2015;36(3):956-65.
160. Brinker F. Herb Contraindications and Drug Interactions, 4th ed. Sandy (OR): Eclectic Medical Publications. 2010.
161. Henney JE. Risk of drug interactions with St. John's wort. JAMA. 283(13):1679 2000.
162. Henderson L et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br. J. Clin. Pharm. 54:349-356, 2002.
163. Mathijssen RHJ et al. Effects of St. John's wort on irinotecan metabolism. J. Nat. Cancer Inst. 94:1247-1249, 2002.
164. Frye RF et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin. Pharmacol. Ther. 76:323-329 2004.
165. Collado-Borrell R et al. Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account. J Cancer Res Clin Oncol. Nov;142(11(:2319-30 2016 .
166. Gordon DW et al. Chaparral ingestion. The broadening spectrum of liver injury caused by herbal medications. JAMA . 273(6): 489-490 1995.
167. Batchelor WB, Heathcote J, Wanless IR. Chaparral-induced hepatic injury. Am J Gastroenterol . 90(5): 831-833. 1995.
168. Grappe F et al. In vitro inhibitory effects of herbal supplements on tamoxifen and irinotecan metabolism. Drug Metabol Drug Interact. 2014;29:269-279.
169. Dresser GK et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther . 72(3): 247-255 2002.
170. Kwatra D et al. Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance. J Pharm Sci. Dec;102(12):4444-54. 2013.
171. Somasagara RR et al. Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells. Int J Oncol. Apr;46(4):1849-57. 2015 .
172. Yung MM et al. Bitter Melon (Momordica charantia) Extract Inhibits Tumorigenicity and Overcomes Cisplatin-Resistance in Ovarian Cancer Cells Through Targeting AMPK Signaling Cascade. Integr Cancer Ther. Sep;15(3):376-89 2016.
173. Limtrakul P, Khantamat O, Pintha K. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract. Cancer Chemother Pharmacol.Dec;54(6):525-30. 2004.
174. Jika C et al. In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Res .43(11): 5151-5155 1983.
175. Pongnikorn S et al. Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy. J Med Assoc Thai .86(1): 61-68 2003.
176. Kaur G, Jaggi AS, Singh N. Exploring the potential effect of Ocimum sanctum in vincristine-induced neuropathic pain in rats. J. Brach. Plex. Periph. Nerve Inj. 5:3 2010.
177. Xu JD, Liu ZH, Chen SZ. Effects of Paeonia-Glycyrrhiza decoction on changes induced by cisplatin in rats. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. 1994;14:673-674.
178. Yoshida T et al. The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer. Support Care Cancer. Mar;17(3):315-20. 2009 .
179. Suh SO et al. Effects of red ginseng upon postoperative immunity and survial in patients with stage III gastric cancer. Am. J. Chin. Med. 30(4):483-494 2002.
180. Jin XC, Sun JZ, Wang X. Effects of xinshuaikang granule on cardiac function and atrial natriuretic polypeptide levels in rabbits with experimental congestive heart failure. Zhongguo Zhong Xi Yi Jie He Za Zhi . 1996;16:424-426.
181. Hasegawa H et al. Reversal of daunomycin and vinblastine resistance in multidrug-resistant P388 leukemia in vitro through enhanced cytotoxicity by triterpenoids. Planta Med . 1995;61:409-413.
182. Gao R, Jin J, Niu Y. Potentiated effects of total saponins of Panax ginseng on inhibition of leukemic cells by cytotoxic drugs. Zhongguo Zhong Xi Yi Jie He Za Zhi . 1999;19:17-19.
183. Jia WW et al. Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapy. Can J Physiol Pharmacol. 2004;82:431-437.
184. Shin HR et al. The cancer-preventive potential of Panax ginseng: a review of human and experimental evidence. Cancer Causes Control. Jul;11(6):565-7 2000.
185. Brinker F. Herbal contraindications and drug interactions plus herbal adjuncts with medicines, 4th edn. Eclectic Medical Publications, 2010.
186. Miller LG. Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med . 158(20): 2200-2211 1998.
187. Shader RI, Greenblatt DJ. Phenelzine and the dream machine -ramblings and reflections. J Clin Psychopharmacol . 5(2): 65 1985.
188. Shader RI, Greenblatt DJ. Bees. ginseng and MAOIs revisited. J Clin Psychopharmacol . 8(4): 235 1988.
189. Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol . 7(3): 201-202 1987.
190. Bahrke MS. Comments on "Manic episode and ginseng: report of a possible case". J Clin Psychopharmacol . 17(2): 140-141 1997.
191. Shin HR et al. The cancer preventive potential of Panax ginseng: A review of human and experimental evidence. Cancer Causes Control . 11(6): 565-576. 2000.
192. Barton DL et al. Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Care Cancer. 18:179-187, 2010.
193. Xu T-M et al. Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. Chin. Med. J. 120(7):584-588, 2007.
194. Zhang QH et al. Protective effects of ginsenoside Rg3 against cyclophosphamide-induced DNA damage and cell apoptosis in mice. Arch. Toxicol. 82:117-123, 2008.
195. Wang Z et al. Ginsenoside Rh2 enhances antitumour activity and decreases genotoxic effect of cyclophosphamide. Bas. Clin. Pharmacol. 98:411-415, 2006.
196. He YS et al. Effects of American ginseng on pharmacokinetics of 5-fluorouracil in rats. Biomed Chromatogr. May;29(5):762-7. 2015 .
197. Mehendale SR et al. Effects of antioxidant herbs on chemotherapy-induced nausea and vomiting in a rat-pica model. Am J Chin Med. 2004;32(6):897-905.
198. Mehendale S et al. American ginseng berry extract and ginsenoside Re attenuate cisplatin-induced kaolin intake in rats. Cancer Chemother Pharmacol.Jul;56(1):63-9. 2005.
199. Lin G et al. Beneficial effects of 20(S)-protopanaxadiol on antitumor activity and toxicity of cyclophosphamide in tumor-bearing mice. Exp Ther Med. Feb;5(2):443-447. 2013 .
200. Kim SM et al. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol. Apr 10;631(1-3):1-9 2010 .
201. Nesher G, Mates M, Zevin S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthr. Rheum., 48(2):571-572, 2003.
202. Borovskaia TG et al. Dilution of the toxic action of 5-fluorouracil on the mucosa of the small intestine in mice using the sap of plantain. Vopr Onkol. 33(7):60-64, 1987.
203. Melese E et al. Evaluation of the antipeptic ulcer activity of the leaf extract of Plantago lanceolata L. in rodents. Phytother. Res. 2011.
204. Takara K et al. Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells. Biol Pharm Bull 28:138. 2005.
205. Shan H et al. Reversal of multidrug resistance of KBV200 cells by triterpenoids isolated from Poria cocos. Planta Med. Mar;78(5):428-33. 2012.
206. Cheng JJ, Chang CC, Chao CH, Lu MK. Characterization of fungal sulfated polysaccharides and their synergistic anticancer effects with doxorubicin. Carbohydr Polym. .Sep 1;90(1):134-9. 2012 .
207. Chen M et al. FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review. Phytother Res. Jul;28(7):976-91 2014 .
208. Udintsev SN, Schakhov VP. Decrease of cyclophosphamide haematotoxicity by Rhodiola rosea root extract in mice with Ehrlich and Lewis transplantable tumours. Eur. J. Cancer. 27(9):1182 1991.
209. Udintsev SN, Krylova SB, Fomina TI. The enhancement of the efficacy of adriamycin by using hepatoprotectors of plant origin in metastases of Ehrlich‟s adenocarcinoma to the liver in mice. Vopr Onkol. 38(10):1217-122 1992.
210. Plouzek CA et al. Inhibition of P-glycoprotein activity and reversal of multidrug resistance in vitro by rosemary extract. Eur. J. Canc. 35(10):1541-1545, 1999.
211. You JS, Pan TL, Lee YS. Protective effects of danshen (Salvia miliorrhiza) on adriamycin-induced cardiac and hepatic toxicity in rats. Phytother. Res. 21:1146-1152, 2007.
212. Hou LL et al. Synergistic antitumor effects of tanshinone II A in combination with cisplatin via apoptosis in the prostate cancer cells. Yao Xue Xue Bao. May;48(5):675-9. 2013 .
213. Sadzuka Y et al. Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol. Lett., 92:1-7, 1997.
214. Pan Q et al. Dibenzocyclooctadiene lingnans: A class of novel inhibitors of P-glycoprotein. Cancer Chemother Pharmacol . 58:99–106 2006.
215. Wan CK et al. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol . 72:824–837 2006.
216. Yoo HH et al. Effects of Schisandra lignans on P-glycoprotein-mediated drug efflux in human intestinal Caco-2. Planta Med . 73:444–450 2007.
217. Mori K et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother. Pharmacol. 51:403-406, 2003.
218. Takasuna K et al. Protective effects of Kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinoteca hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res. 86:978-984, 1995.
219. Kaplya OA et al. Effect of baikal skullcap extract administered alone or in combination with cyclophosphamide on natural cytotoxicity system in mice with Lewis lung carcinoma. . Bull Exp Biol Med. 2004 .
220. Razina TG et al. Enhancement of the selectivity of the action of the cytostatics cyclophosphane and 5-fluorouracil by using an extract of the Baikal skullcap in an experiment. Vopr. Onkol. 33(2):80-84, 19.
221. Yu CP et al. Increased Systemic Exposure of Methotrexate by a Polyphenol-Rich Herb via Modulation on Efflux Transporters Multidrug Resistance-Associated Protein 2 and Breast Cancer Resistance Protein. J Pharm Sci. Jan;105(1):343-9. 2016 .
222. Perez AT et al. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. Feb;120(1):111-8. 2010.
223. Lee YW et al. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study. Cancer. May 1;120(9):1338-44. 2014 .
224. Dai Z et al. The effect-enhancing and toxicity-reducing action of the extract of herba Scutellariae barbatae for chemotherapy in hepatoma H22 tumor-bearing mice. J Tradit Chin Med. Sep;28(3):205-10. 2008 .
225. Li J et al. Sensitisation of ovarian cancer cells to cisplatin by flavonoids from Scutellaria barbata. Nat Prod Res. 28(10):683-9. 2014;.
226. Bokemeyer C et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity . Br J Cancer . 74(12):2036-2041. 1996.
227. Gaedeke J et al. Cisplatin nephrotoxicity and protection by silibinin. . Nephrol.Dial.Transplant. 11(1):55-62. 1996;.
228. Scambia G et al. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur J Cancer . 32A:877-882. 1996;.
229. Giacomelli S et al. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci . 70:1447-1459 2002;.
230. Dhanalakshmi S et al. Silibinin sensitizes human prostate carcinoma DU145 cells to cisplatin- and carboplatin-induced growth inhibition and apoptotic death. Int J Cancer . 106:699-705 2003;.
231. Chlopcikova S et al. Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res . 18:107-110 2004.
232. Psotova J et al. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res . 16 Suppl 1:S63-67. 2002;.
233. Tyagi AK et al. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. Clin Cancer Res . 8:3512-3519. 2002.
234. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther. 304:1258-1267. 2003.
235. Rastegar H et al. The role of milk thistle extract in breast carcinoma cell line (MCF-7) apoptosis with doxorubicin. Acta Med Iran. 51:591-598. 2013.
236. Sadava D, Kane SE. Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett. 339:102-106. 2013.
237. Cufí S et al. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food Chem Toxicol. Oct;60:360 2013.
238. Ladas EJ et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. Jan 15;116(2):506-13. 2010 .
239. van Erp NP et al. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res. Nov 1;11(21):7800-6. 2005.
240. Gurley BJ et al. in vivo Assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther . 76(5): 428-440. 2004.
241. Beckmann-Knopp S et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol. 86(6): 250-256. 2000.
242. de Sousa NC et al. Modulatory effects of Tabebuia impetiginosa (Lamiales, Bignoniaceae) on doxorubicin-induced somatic mutation and recombination in Drosophila melanogaster. Genet Mol Biol. Apr;32(2):382-8 2009.
243. Patel NM et al. Paclitaxel sensitivity of breast cancer cells with constitutively active NG-kB is enhanced by IkBa super-repressor and parthenolide. Oncogene. 19:4159-4169 2000.
244. Miglietta A et al. Microtubule-interfering activity of parthenolide. Chemico-Biol. Interact. 149:165-173 2004.
245. Cory AH, Cory JG. Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NF-κB activation, on drug-resistant mouse leukemia L1210 cells. Anticancer Res. 22:3805-3809 2002.
246. Sweeney CJ et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther . 4:1004-1012 2005;.
247. DeGraffenried LA et al. NF-κB inhibition markedly enhances sensitivity of resistant breast cancer tumor cells to tamoxifen. Ann Oncol . 15:885-890. 2004.
248. Wang Y et al. The red clover (Trifolium pratense) isoflavone biochanin A inhibits aromatase activity and expression. Br J Nutr. Feb;99(2):303-10. 2008.
249. Roberts DW et al. Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pratense (red clover). J Agric Food Chem. Oct 20;52(21):66 2004 .
250. van Meeuwen JA et al. (Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture. Toxicol Appl Pharmacol. Jun 15;221(3):372-83. 2007.
251. Raju KS et al. No effect on pharmacokinetics of tamoxifen and 4-hydroxytamoxifen by multiple doses of red clover capsule in rats. Sci Rep. Nov 4;5:16126. 2015 .
252. Fritz H et al. Soy, red clover, and isoflavones and breast cancer: a systematic review. . PLoS One. Nov 28;8(11):e81968. 2013 .
253. Orr A, Parker R. red clover causing symptoms suggestive of methotrexate toxicity in a patient on high-dose methotrexate. Menopause International . Sep; Vol. 19 (3), pp. 133-4. 2013 .
254. Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P- glycoprotein-mediated transport. J. Pharmacol. Exp. Therap. 304(3):1258-1267 2003.
255. Bhatia K et al. Aqueous extract of Trigonella foenum-graecum L. ameliorates additive urotoxicity of buthionine sulfoximine and cyclophosphamide in mice. Food Chem Toxicol. .Oct;44(10):1744-50. 2006 .
256. Hegazy MG, Emam MA. Ethanolic extract of Trigonella foenum graecum attenuates cisplatin-induced nephro- and hepatotoxicities in rats. Cell Mol Biol (Noisy-le-grand). Nov 25;61(7):81-7. 2015 .
257. Shishodia S, Aggarwal BB. Diosgenin inhibits osteoclastogenesis, invasion, and proliferation through the downregulation of Akt, IB kinase activation and NF-B-regulated gene expression. Oncogene. 25:1463- 1473 2006.
258. Zhao J et al. Anti-aromatase activity of the constituents from damiana (Turnera diffusa). J Ethnopharmacol. Dec 8;120(3):387-93. 2008.
259. Zava DT, Dollbaum CM, and Blen M. Estrogen and progestin bioactivity of foods, herbs, and spices. Proc.Soc.Exp Biol Med . 217(3):369-378. 1998.
260. Araújo MdoCS et al. Uncaria tomentosa-Adjuvant Treatment for Breast Cancer: Clinical Trial. Evidence-based Complementary and Alternative Medicine . Article ID:676984, 8 pages 2012, .
261. Sheng Y, Pero RW, Wagner H. Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from Uncaria tomentosa. Phytomedicine. Apr;7(2):137-43. 2000.
262. Farias IL et al. Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial. Evidence-Based Complementary and Alternative Medicine. Article ID 892182, 8 pages 2012.
263. Sheng Y, Pero RW, Wagner H. Treatment of chemotherapy-induced leukopenia in a rat model with aqueous extract from Uncaria tomentosa. Phytomedicine.Apr;7(2):137-43. 2000.
264. Budzinski JW et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine . 7(4): 273-282. 2000.
265. Sandoval M et al. Cat's claw inhibits TNFalpha production and scavenges free radicals: Role in cytoprotection. Free Radic Biol Med . 29(1): 71-78 2000.
266. Ozkol H et al. Ameliorative influence of Urtica dioica L against cisplatin-induced toxicity in mice bearing Ehrlich ascites carcinoma. Drug Chem Toxicol. 35:251-257. 2012.
267. European Medicines Agency. Assessment report on Urtica dioica L., Urtica urens L., their hybrids or their mixtures, radix. Committee on Herbal Medicinal Products (HMPC). September 24 , 2012.
268. Chrubasik JE et al. A comprehensive review on the stinging nettle effect and efficacy profiles. Part II: Urticae radix. Phytomed. 14: 568-569 2007.
269. Hartmann RW, Mark M, Soldati F. Inhibition of 5a-reductase and aromatase by PHL-00801 (Prostatonins), a combination of PY 102 (Pygeum africanum) and UR 102 (Urtica dioica) extracts. Phytomedicine . 3: 121-128 1996, .
270. Lefebvre T et al. in vitro Activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharm Sci . 7(2): 265-273 2004.
271. Donovan JL et al. . Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos . 32(12): 1333-1336 2004.
272. Biswal BM et al. Effect of Withania somnifera (ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther. Jul;12(4):312-22. 2013 .
273. Davis L, Kuttan G. Suppressive effect of cyclophosphamide-induced toxicity by Withania somnifera extract in mice. J. Ethnopharm.62:209-214, 1998.
274. Diwanay S, Chitre D, Patwardhan B. Immunoprotection by botanical drugs in cancer chemotherapy. J. Ethnopharm. 90:49-55 2004.
275. Davis L, Kuttan G. Effect of Withania somnifera on cyclophosphamide-induced urotoxicity. Cancer Lett. 148:9-17 2000.
276. Ziauddin M et al. Studies on the immunomodulatory effects of ashwagandha. J. Ethnopharm. 50:69-76 1996.
277. Senthilnathan P et al. Chemotherapeutic efficacy of paclitaxel in combination with Withania somnifera on benzo(a)pyrene-induced experimental lung cancer. Cancer Sci. 97(7):658-664, 2006.
278. Gupta YK et al. Reversal of paclitaxel induced neutropenia by Withania somnifera in mice. Indian J Physiol Pharmacol. Apr;45(2):253-7. 2001 .
279. Yamahara J et al. Inhibition of cytotoxic drug-induced vomiting in suncus by a ginger constituent. J. Ethnopharm. 27:353-355, 1989.
280. Levine ME et al. Protein and ginger for the treatment of chemotherapy-induced delayed nausea. J. Altern. Compl. Med. 14(5):545-551, 2008.
281. Manusirivithaya S et al. Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int. J. Gynecol. Cancer. 14:1063-1069, 2004.
282. Sontakke S, Thawani V, Naik MS. ginger as an antiemetic in nausea and vomiting induced by chemotherapy: a randomized, dross-over, double blind study. Indian J. Pharmacol. 35:32-36, 2003.
283. Panahi Y et al. Effect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial. Integr. Cancer Ther. Feb. 7 2012.
284. Pillai AK et al. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr. Blood Cancer. 56:234-238 , 2011.
285. Zick SM et al. Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer . 17: 563-572. 2009.
286. Meyer K et al. Zingiber officinale (ginger) used to prevent 8-MOP associated nausea. Derm. Nurs. 7(4):242-244, 1995.
287. Ansari M et al. Efficacy of ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin-Based Chemotherapy. Asian Pac J Cancer Prev. 17(8):3877-80. 2016.
288. Bilgi N et al. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother. 2010;44:926-928.
289. Jung SY et al. Korean Red Ginseng Extract Enhances the Anticancer Effects of Imatinib Mesylate Through Abrogation p38 and STAT5 Activation in KBM-5 Cells. Phytother Res. Jul;29(7):1062-72. 2015 .